Strong First Quarter but Market Technicals send Red Flags

The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.

The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.

Stock rose on Thursday on optimism that rate hikes may be over. The Commerce Department said that in September, new orders for U.S. manufactured goods rose 2.8% to $601.5 billion following a 1.0% increase in August. On Friday morning, investors will be looking at the jobs report for October. On the earnings front, Apple reported after the bell. Although the company beat consensus it issued a cautious outlook. The S&P 500 rose 1.9%, the Dow 1.7% and the Nasdaq was up 1.8%. Crude oil rose nearly 1% to $82 per barrel, while gold traded near $1991 per ounce.

Proper leadership for the stock market is one of the most important indicators of the health of a bull market. This takes on even more importance because the major indices are cap-weighted, with some industries and sectors heavily weighted in the indices and others not at all. In addition, the psyche of a bull market reflects which stocks are leading. Are they higher-beta names with strong growth revenues and EPS prospects that can add some real alpha to a portfolio? Or are they lower-beta names, where slow and steady is the name of the game.

The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.

Monday Tee Up: The Fed, Jobs, Earnings

The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.

The current advance by the large-cap indices has occurred because of some very nice gains in the mega-cap stocks, that within the context of an overall neutral-to-poor period of market breadth. Over the past six months (since the start of October) as well as year-to-date, the leaderboard is littered with mega-caps, mostly from the Technology sector. At the same time, the Nasdaq 100 advance-decline line has improved -- but remains range bound. Interestingly, we heard the same complaint in the late 1990s -- which was a pretty good time for the QQQs and the S&P 500.

In this edition, global oil inventories face future; feeling the internet's backbone; and initiating coverage of Qualys; and Lithium Americas, Bausch & Lomb and Macy's.

In this edition, railroads may be in for a bumpy ride; ESG has some opportunities; biotechs innovate; and Constellation Brands, Autodesk, and Tencent.

In this edition, railroads may be in for a bumpy ride; ESG has some opportunities; biotechs innovate; and Constellation Brands, Autodesk, and Tencent.

The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.

Value stocks -- a market segment that includes high-yield stocks -- outperformed growth stocks in 2022 for the first time since 2016. Indeed, for the past decade, the performance record has favored growth. Since 2010, the Russell 1000 Growth Index has climbed more than 500%, compared to an advance of almost 300% for the Russell 1000 Value Index. In eight of the past 10 years, growth stocks have topped value stocks. That hasn't always been the case. In the 2000-2010 decade, which included two bear markets and the Great Recession, value stocks were better performers than growth stocks, advancing an admittedly low 8% -- but still better than growth, which declined 15% during the decade. Value investors trace their roots to the famous "Security Analysis" textbook, written in 1934 (the year Argus Research was founded) by Ben Graham, an economics professor at Columbia University. Warren Buffett was one of his students. Looking ahead, the rollout of COVID-19 vaccines has given a lift to some of the cyclical companies that have lagged in recent years, and value stocks outpaced growth stocks in the past year. Now, the Federal Reserve is lifting interest rates to fend off inflation, which likely will cap multiple expansion for growth companies. In any event, value is the place to achieve income. The current yield on the iShares Russell 1000 Value Index ETF is 2.2%, compared to the 0.9% current yield on the iShares Russell 1000 Growth Index ETF. For our list this week, we have screened our coverage universe for stocks that are BUY-rated by Argus Research analysts, have a Financial Strength rating of at least Medium, and have a yield of 4.0% or higher. Here's a baker's dozen that meet the criteria.

Value stocks -- a market segment that includes high-yield stocks -- outperformed growth stocks in 2022 for the first time since 2016. Indeed, for the past decade, the performance record has favored growth. But the tide turned in 2022. The rollout of COVID-19 vaccines gave a lift to some of the cyclical companies (energy companies and regional banks) that had lagged in recent quarters, and value stocks outpaced growth stocks over the past year. Meanwhile, the Federal Reserve continues to lift interest rates to fend off inflation, which could possibly cap multiple expansion for growth companies for a few more quarters. Regardless, the value sector is the place to achieve income. The current yield on the iShares Russell 1000 Value Index ETF is 2.2%, compared to the 0.9% current yield on the iShares Russell 1000 Growth Index ETF. For our High-Yield Theme Model Portfolio, we are seeking stocks with yields of at least 3.0%. This moves us deep into the value segment of the market.

The Portfolio Selector features the Argus Focus List, a group of 30 "best idea" stocks generated and regularly updated by Argus' analysts and investment policy committee. It also includes the director of research’s monthly investment strategy column, stock recommendations and sector picks, economic forecasts, and an asset allocation model. This month, the Focus List additions are Raytheon Teches Corporatio (RTX); Biogen Inc (BIIB); Coca-Cola Co (KO); Shopify Inc (SHOP) and the Focus List deletions are Hormel Foods Corp. (HRL); General Dynamics Corp. (GD); AbbVie Inc (ABBV); NXP Semiconductors NV (NXPI).

Vickers Stock Research, a subsidiary of Argus Research Group, tracks and analyzes insider trading and institutional ownership trends. Form 13-Fs are due 45 days after the end of calendar quarters, and have now come in from 3Q22. We like to review the 13Fs of the major activist investors, including Carl Icahn, Trian Fund Management, Jana Partners, and ValueAct Holdings (among others) in order to determine their core holdings and new purchases. Activist investing has evolved in recent years and is now less about generating a short-term return on an underpriced stock and more about achieving long-term returns through an active management/investor partnership. Here are some recent new purchases and key holdings of Activist investors, according to Vickers.

Stocks were mixed on Friday morning, with solid gains in the Healthcare, Consumer Staples, and Utility sectors, and losses in Energy and Consumer Discretionary. On the earnings front, Gap Inc. rose strongly after the retailer posted better-than-expected 3Q earnings, helped by increased demand for formal clothing. Applied Materials shares also rose following strong fiscal 4Q sales and earnings and favorable 1Q guidance. The Dow rose 0.4%, the S&P rose 0.1%, and the Nasdaq fell 0.3%. Crude oil fell more than 3% to $79 per barrel, while gold fell $6 to $1757 per ounce.

Value stocks -- a market segment that includes high-yield stocks -- are outperforming growth stocks in 2022 for the first time since 2016. Indeed, for the past decade, the performance record has favored growth. Since 2010, the Russell 1000 Growth Index has climbed more than 600%, compared to an advance of 300% for the Russell 1000 Value Index. In nine of the past 10 years, growth stocks have topped value stocks. That wasn't always the case. In the 2000-2010 decade, which included two bear markets and the Great Recession, value stocks were better performers than growth stocks, advancing an admittedly low 8% (but still better than growth, which declined 15% during the decade). Value investors trace their roots to the famous "Security Analysis" textbook, written by Ben Graham, an economics professor at Columbia University. Warren Buffett was one of his students. Looking ahead, the roll-out of COVID-19 vaccines has given a lift to some of the cyclical companies (energy companies and regional banks) that have lagged in recent quarters, and value stocks have kept up the pace with growth stocks in the past year. Now, the Federal Reserve is lifting interest rates to fend off inflation, which will likely cap multiple expansion for growth companies. In any event, value is the place to achieve income. The current yield on the iShares Russell 1000 Value Index ETF is 2.1%, compared to the 0.8% current yield on the iShares Russell 1000 Growth Index ETF. For our list this week, we have screened our coverage universe for stocks that are BUY-rated at Argus Research, have an Argus Financial Strength rating of at least Medium, and have a yield of 4.0% or higher. Here's a baker's dozen that meet the criteria.

After rallying across July and most of August, the stock market fell hard on Monday, posting its worst single-day loss since June. In that month, stocks fell hard on bad inflation data. This time, there was no evident driver of the selloff, except potential profit-taking after strong gains were logged over the past six weeks.

Value stocks -- a market segment that includes high-yield stocks -- are outperforming growth stocks in 2022 for the first time since 2016. Indeed, for the past decade, the performance record has favored growth. In nine of the past 10 years, growth stocks have topped value stocks. But the tide may be turning. The rollout of COVID-19 vaccines has given a lift to some of the cyclical companies (energy companies and regional banks) that have lagged in recent quarters, and value stocks have kept up the pace with growth stocks in the past year. Now, the Federal Reserve lifting interest rates to fend off inflation, which will likely cap multiple expansion for growth companies. Regardless, the value sector is the place to achieve income. The current yield on the iShares Russell 1000 Value Index ETF is 2.1%, compared to the 0.8% current yield on the iShares Russell 1000 Growth Index ETF. For our High-Yield Theme Model Portfolio, we are seeking stocks with yields of at least 3.0%. This moves us deep into the value segment of the market.

The S&P 500 fell by 1.2% on Tuesday, the Nasdaq gave up 1.9%, and the QQQs fell 2% as investors brace for a major EPS reporting week as well as today's FOMC decision. At this point, and since the mid-June low, all three of the above indices look about the same on a daily chart. The "500" fell right to its 50-day average yesterday, while the Nasdaq and QQQs finished just above their 50-day average. All three have broken below recent breakout levels, but only by a small amount -- so the short-term uptrend is intact.

The S&P 500 fell by 1.2% on Tuesday, the Nasdaq gave up 1.9%, and the QQQs fell 2% as investors brace for a major EPS reporting week as well as today's FOMC decision. At this point, and since the mid-June low, all three of the above indices look about the same on a daily chart. The "500" fell right to its 50-day average yesterday, while the Nasdaq and QQQs finished just above their 50-day average. All three have broken below recent breakout levels, but only by a small amount -- so the short-term uptrend is intact.

Argus has published its latest Portfolio Selector, which features its popular Focus List. Each month, Director of Research Jim Kelleher, CFA, surveys the team of Argus Research industry analysts for their timeliest recommendations out of the company's fundamental universe of approximately 500 stocks. The Focus List typically includes 30 stocks: turnover is high, as Director of Research Kelleher typically adds three or four new stocks per month. Below are the latest additions, all of which are rated BUY at Argus.

The Portfolio Selector features the Argus Focus List, a group of 30 "best idea" stocks generated and regularly updated by Argus' analysts and investment policy committee. It also includes the director of research’s monthly investment strategy column, stock recommendations and sector picks, economic forecasts, and an asset allocation model. This month, the Focus List additions are AbbVie Inc (ABBV); Monster Beverage Corp. (MNST); ASML Holding NV (ASML); Sempra Energy (SRE); Morgan Stanley (MS) and the Focus List deletions are Sysco Corp. (SYY); Lam Research Corp. (LRCX); Lazard Ltd. (LAZ); Moderna Inc (MRNA).

Commodities continue to get shellacked, Treasury yields across the curve are still falling, people are starting to suggest that the Federal Reserve won't have to tighten as much as many thought just a month or two ago, recession fears (or worries that we are already in one) are rising quickly, EPS season is almost upon us (with many believing 2022 numbers are far too high), crypto remains in the dumpster, and the horrendous invasion of Ukraine never ends.

Dividend income, an important element of total return, is often overlooked amid gyrations in the stock market. Between 1930 and 2012, dividend income accounted for 42% of the total return of the S&P 500, according to Hartford Funds. And that's just the average. In some decades, dividends accounted for more than 50% of total returns and even 100% of returns. More recently, dividends have accounted for 15%-20% of returns. Still, in 2018, dividend payments softened the blow when most market indices declined as the Federal Reserve hiked rates. The pattern is being repeated in 2022 as well. Not all dividends are created equal, though, and it is important to understand the difference between the two main categories: high-yield stocks and dividend-growth stocks.

This is among our most important themes for 2022, and stretches across industries. We think companies that consistently raise their dividends at a double-digit rate are sending off three important signals amid the recent market volatility: 1) the company's balance sheet is strong enough to pay a dividend; 2) management is focused on providing shareholder returns; and 3) management is confident enough in the near-term outlook to raise the payout aggressively. The third factor is especially important as the pandemic upended the nation's recent record of long-term economic growth. Here are 19 stocks that meet our double-digit dividend test and are on the Argus BUY List. They are also holdings in our Dividend Growth Separately Managed Account and in the Dividend Growers Total Return Trust, sponsored by SmartTrust.

Sentiment continues to get more bearish -- and eventually that will be bullish. The five-day CBOE equity-only put/call (P/C) hit 0.77 on May 12, the highest level since the correction started. Yet that is not near prior peaks during corrections/bear markets (when it ran from 0.85 to over 1.00). The smallest option traders spent 30% or more of their volume buying put options to open. They also spent more on put premiums than on call premiums. Both events are very rare -- and when this happens, the market often moves higher over the next year.

Our rating on the Healthcare sector is Over-Weight. Consumers are now more willing to spend on lifestyle enhancements along with necessary spending on life-saving treatments. In addition, the survival of the Affordable Care Act has kept the ranks of insured U.S. citizens above the historical average, further increasing consumer spending on healthcare services and products. Meanwhile, companies with experience in diagnostic testing, vaccines, and antiviral medicines, as well as suppliers of protective equipment and other hospital products, should benefit from efforts to contain the pandemic. The sector accounts for 13.7% of the S&P 500, and includes companies in the pharmaceuticals, medical devices, healthcare services, and insurance industries. The sector is outperforming the market thus far in 2022, with a gain of 1.3% through early April, while the S&P 500 has declined 6%. The following are examples of how we use our analysts' Healthcare sector ideas in our Focus List and Model Portfolios. All stocks are rated BUY at Argus.

The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.

The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.

Value stocks -- a market segment that includes high-yield stocks -- are outperforming growth stocks in 2022. For the past decade, the performance record has favored growth, but the tide may be turning. The rollout of COVID-19 vaccines has given a lift to some of the cyclical companies (energy companies and regional banks) that have lagged in recent quarters, and value stocks have kept up the pace with growth stocks in the past year. Now, the Federal Reserve is poised to lift interest rates to fend off inflation, which will likely cap multiple expansion for growth companies. Regardless, the value sector is the place to achieve income. The current yield on the iShares Russell 1000 Value Index ETF is 1.6%, compared to the 0.5% current yield on the iShares Russell 1000 Growth Index ETF. For our High-Yield Theme Model Portfolio, we are seeking stocks with yields of at least 3.0%. This moves us deep into the value segment of the market.

Stocks fell on Thursday morning following more signs of accelerating inflation. The Labor Department said that U.S. consumer prices rose at a 7.5% annualized rate in January, up from 7.0% in December. The reading exceeded the Bloomberg consensus forecast of 7.3% and was the highest since 1982. The core CPI excluding food and energy rose an annualized 6.0%, up from 5.5% in December. The Dow fell 0.2%, the S&P 0.3%, and the Nasdaq 0.3%. Crude oil rose more than 2% to $92 per barrel, while gold rose $5 to $1841 per ounce.

This edition features our annual pharmaceutical pipeline, a fresh look at Barry Callebaut's chocolate operation, the buzz around RingCentral, and SAP, Subsea 7, and Just Eat Takeaway.

Stocks finished mostly higher on Thursday as investors weighed a new round of earnings reports and continued to assess the Fed's tapering plan. Employment data was strong. The Labor Department said that first-time claims for state unemployment benefits fell to 269,000 for the week ended October 30, down from 283,000 a week earlier and below the Bloomberg consensus of 275,000. Continuing claims of 2.105 million were also down from the prior week and below consensus. The data came ahead of the government's October employment report on Friday morning. The consensus calls for the addition of 450,000 new payroll jobs after an increase of 194,000 in September, and a decrease in the unemployment rate to 4.7%. The Dow fell 0.09%, the S&P rose 0.42%, and the Nasdaq rose 0.81%. Crude oil fell 2% to $79 per barrel, while gold rose $29 to $1793 per ounce.

Stocks finished mostly higher on Thursday as investors weighed a new round of earnings reports and continued to assess the Fed's tapering plan. Employment data was strong. The Labor Department said that first-time claims for state unemployment benefits fell to 269,000 for the week ended October 30, down from 283,000 a week earlier and below the Bloomberg consensus of 275,000. Continuing claims of 2.105 million were also down from the prior week and below consensus. The data came ahead of the government's October employment report on Friday morning. The consensus calls for the addition of 450,000 new payroll jobs after an increase of 194,000 in September, and a decrease in the unemployment rate to 4.7%. The Dow fell 0.09%, the S&P rose 0.42%, and the Nasdaq rose 0.81%. Crude oil fell 2% to $79 per barrel, while gold rose $29 to $1793 per ounce.

The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.

Vickers Stock Research, a subsidiary of Argus Research Group, tracks insider trading and institutional ownership. Form 13-Fs have now come in from 2Q21. We review the 13Fs of major activist investors, including Carl Icahn, Trian Fund Management, Jana Partners, and ValueAct Holdings, among others. Activist investing has evolved in and is now less about generating a short-term return on an underpriced stock and more about achieving long-term returns through an active management/investor partnership. Here are some recent new purchases and key holdings of Activist investors, according to Vickers.

Value stocks are outperforming growth in 2021 for the first time since 2016. While a recent rally in growth stocks has narrowed the performance advantage for value in the year to date, an environment of historically low interest rates is one in which many investors are still searching for high levels of income -- which often can be found in value stocks. When we look for attractive high-yield/deep-value stocks at Argus, we look for low valuations on metrics such as price/earnings, price/sales, price/book, yield, and price/cash flow. We also look for companies with clean balance sheets, high levels of profitability, high-quality earnings, and experienced management teams. We seek to avoid companies in industries that are in secular decline, or with dividend yields that are so high that the payout is clearly at risk. Based on numerous requests from clients, we have designed a portfolio of companies that are BUY-rated at Argus Research, have a Financial Strength rating of at least Medium, and have a yield of 3.0% or higher.

Second-quarter earnings announcements are nearly complete, with some 90% of S&P 500 companies having reported. The profit recovery from the depths of the pandemic low in 2Q20 was been swift, with earnings growth of 93% in 2Q21, according to Refinitiv. But earnings do not look good just on a relative basis -- the $53.93 projected to be earned by S&P 500 companies for the second quarter is the highest ever for the index. Investors can now turn their attention to the third quarter, when earnings are expected to rise a still-strong 30% year-over-year. Our analysts are always on the lookout for companies that raise their outlooks during earnings season. Management's ability to "raise guidance" can often be a catalyst to strong returns in the quarters ahead. Here are 20 BUY-rated companies in Argus coverage for which management has raised guidance or increased its outlook during the 2Q21 EPS reporting season.

Stocks kept momentum going in July and August. Our analysts have been progressing through earnings season and have come across many stocks that have approached target prices. We set targets through our valuation framework, which includes analysis of historical multiples, peer multiples, and future dividends and cash flows. After adjusting for the latest information, here are some of the stocks on which we raised target prices over the past month. All of the following stocks are rated BUY at Argus.

Trying to Get to Normal: Our Monthly Survey of the Economy, Interest Rates, and Markets

Consumers are now more willing to spend on lifestyle enhancements along with necessary spending on life-saving treatments. In addition, the survival of the Affordable Care Act has kept the ranks of insured U.S. citizens above the historical average, further increasing consumer spending on healthcare services and products. Meanwhile, companies with experience in diagnostic testing, vaccines, and antiviral medicines, as well as suppliers of protective equipment and other hospital products, should benefit from efforts to contain the coronavirus pandemic. The sector accounts for 13.0% of the S&P 500, and includes companies in the pharmaceuticals, medical devices, healthcare services, and insurance industries. The sector is underperforming the market thus far in 2021, with a gain of 12.9%. We think the sector should account for 15-17% of diversified portfolios. Here is how we use our analysts' Financial Services sector ideas in our Focus List and Model Portfolios. All stocks are rated BUY at Argus.